Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 31, Issue 7, 2016, Pages 1088-1099

  Leifheit Nestler, Maren ^a   Siemer, Robert Große ^a   Flasbart, Kathrin ^a   Richter, Beatrice ^a   Kirchhoff, Felix ^a   Ziegler, Wolfgang H ^a   Klintschar, Michael ^a   Becker, Jan U ^b   Erbersdobler, Andreas ^c   Aufricht, Christoph ^d   Seeman, Tomas ^e   Fischer, Dagmar Christiane ^c   Faul, Christian ^f   Haffner, Dieter ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Fibroblast growth factor 23; Fibroblast growth factor receptor 4; Klotho; Left ventricular hypertrophy

Indexed keywords

CALCINEURIN; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KLOTHO PROTEIN; PHOSPHATE; TRANSCRIPTION FACTOR NFAT; BIOLOGICAL MARKER; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ARTICLE; CARDIAC MUSCLE CELL; CASE CONTROL STUDY; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOLOGY;

BIOMARKERS; CASE-CONTROL STUDIES; CHILD; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84983740565     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv421     Document Type: Article

References (55)

1. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592
2. Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158-169
3. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 2012;23:578-585
4. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305
5. Parekh RS, Carroll CE, Wolfe RA et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002;141:191-197
6. Gutiérrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-2552
7. Yang K, Wang C, Nie L et al. Klotho protects against indoxyl sulphate-induced myocardial hypertrophy. J Am Soc Nephrol 2015;26:2434-2446
8. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408
9. Mitsnefes MM, Flynn J, Cohn S et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010;21:137-144
10. Wang H, Liu J, Xao XD et al. Multidirectional myocardial systolic function in hemodialysis patients with preserved left ventricular ejection fraction and different left ventricular geometry. Nephrol Dial Transplant 2012;27:4422-4429
11. Bakkaloglu SA, Borzych D, Soo Ha I et al. Cardiac geometry in children receiving chronic peritoneal dialysis: findings from the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Clin J Am Soc Nephrol 2011;6:1926-1933
12. Shimada T, Muto T, Urakawa I et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002;143:3179-3182
13. Gutierrez OM, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-2215
14. Portale AA, Wolf M, Juppner H et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014;9:344-353
15. Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol 2013;180:47-63
16. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-1378
17. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;7:737-747
18. Viaene L, Bammens B, Meijers BK et al. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant 2012;27:2017-2022
19. Isakova T, Xie H, Barchi-Chung A et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011;6:2688-2695
20. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010;95:578-585
21. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-2439
22. US Renal Data System. USRDS 2014 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
23. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011;22:956-966
24. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006;281:6120-6123
25. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-774
26. Schmid C, Neidert MC, Tschopp O et al. Growth hormone and Klotho. J Endocrinol 2013;219:R37-R57
27. Hu MC, Shi M, Cho HJ et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 2015;26:1290-1302
28. Xie J, Yoon J, An SW et al. Soluble Klotho protects against uremic cardiomyopathy independent of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 2015;26:1150-1160
29. Touchberry CD, Green TM, Tchikrizov V et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013;304:E863-E873
30. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 2012;21:369-375
31. Grabner A, Amaral AP, Schramm K et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015;22:1020-1032
32. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45
33. Molkentin JD, Lu JR, Antos CL et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228
34. Rao A. Signaling to gene expression: calcium, calcineurin and NFAT. Nat Immunol 2009;10:3-5
35. Gupta M, Gupta MP, Arcilla RA et al. Cardiomyocytes and non-muscle cells in cardiac hypertrophy: a molecular perspective. Prog Pediatr Cardiol 1998;9:183-197
36. Jongbloed F, Galassi A, Cozzolino M et al. Clinical significance of FGF-23 measurement in dialysis patients. Clin Nephrol 2011;76:201-209
37. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-1315
38. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007;18:2683-2688
39. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014;10:268-278
40. Seeherunvong W, Abitbol CL, Chandar J et al. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol 2012;27:2129-2136
41. Xanthakis V, Larson MG, Wollert KC et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc 2013;2:e000399
42. Smith RC, O'Bryan LM, Farrow EG et al. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 2012;122:4710-4715
43. Lindberg K, Amin R, Moe OW et al. The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 2014;25:2169-2175
44. Akimoto T, Kimura T, Watanabe Y et al. The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplant Proc 2013;45:134-146
45. Juppner H, Wolf M. alphaKlotho: FGF23 coreceptor and FGF23-regulating hormone. J Clin Invest 2012;122:4336-4339
46. Tsujikawa H, Kurotaki Y, Fujimori T et al. Klotho, a gene related to a syndromeresembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003;17:2393-2403
47. Zhang X, Ibrahimi OA, Olsen SK et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281:15694-15700
48. Molkentin JD. Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells. Circ Res 2013;113:16-19
49. Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol 2013;14:38-48
50. Maillet M, Davis J, Auger-Messier M et al. Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function. J Biol Chem 2010;285:6716-6724
51. Di Marco GS, Reuter S, Kentrup D et al. Cardioprotective effect of calcineurin inhibition in an animal model of renal disease. Eur Heart J 2011;32:1935-1945
52. Wesseling-Perry K, Pereira RC, Tsai E et al. FGF23 and mineral metabolism in the early post-renal transplantation period. Pediatr Nephrol 2013;28:2207-2215
53. Sanchez Fructuoso AI, Maestro ML, Perez-Flores I et al. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Nephrol Dial Transplant 2012;27:4227-4235
54. Di Marco GS, Reuter S, Kentrup D et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant 2014;29:2028-2035
55. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122:2543-2553